A phase Ib study of second-line therapy with panitumumab, irinotecan, and everolimus (PIE) in metastatic colorectal cancer (mCRC) with KRAS wild type (WT).
Amanda Rose Townsend
Research Funding - Amgen; Novartis
Louise Pirc
No relevant relationships to disclose
Pamela Cooper
No relevant relationships to disclose
Niall C. Tebbutt
Consultant or Advisory Role - Amgen
Research Funding - Amgen; Novartis
Christos Stelios Karapetis
Consultant or Advisory Role - Amgen (U)
Nimit Singhal
No relevant relationships to disclose
Timothy Jay Price
Consultant or Advisory Role - Amgen (U)
Other Remuneration - Amgen